Synthesis and Biological Evaluation of New Creatine Fatty Esters Revealed Dodecyl Creatine Ester as a Promising Drug Candidate for the Treatment of the Creatine Transporter Deficiency
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The creatine transporter deficiency is a neurological disease caused by impairment of the creatine transporter SLC6A8, resulting in mental retardation associated with a complete absence of creatine within the brain and cellular energy perturbation of neuronal cells. One of the therapeutic hypotheses was to administer lipophilic creatine derivatives which are (1) thought to have better permeability through the cell membrane and (2) would not rely on the activity of SLC6A8 to penetrate the brain. Here, we synthesized creatine fatty esters through original organic chemistry process. A screening on an in vitro rat primary cell-based blood-brain barrier model and on a rat primary neuronal cells model demonstrated interesting properties of these prodrugs to incorporate into endothelial, astroglial, and neuronal cells according to a structure-activity relationship. Dodecyl creatine ester showed then a 20-fold increase in creatine content in pathological human fibroblasts compared with the endogenous creatine content, stating that it could be a promising drug candidate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, recent work has demonstrated early promise with the use of creatine fatty esters and lipid nanocapsules as a nutrition-based therapeutic treatment for creatine transporter deficiency [55,56].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [55]
Citations
Cites
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
X-Linked Creatine-Transporter Gene (SLC6A8) Defect: A New Creatine-Deficiency Syndrome
Salomons, G. S., van Dooren, S. J. M., Verhoeven, N. M., Cecil, K. M., Ball, W. S., Degrauw, T. J., & Jakobs, C. (2001) · The American Journal of Human Genetics · doi:10.1086/320595 · Cited by 396
Stöckler, S., Hanefeld, F., & Frahm, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04116-5 · Cited by 240
Ohtsuki, S., Tachikawa, M., Takanaga, H., Shimizu, H., Watanabe, M., Hosoya, K.-I., & Terasaki, T. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200211000-00006 · Cited by 196
Schulze, A. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1022443503883 · Cited by 189
Cecil, K. M., Salomons, G. S., Ball, W. S., Wong, B., Chuck, G., Verhoeven, N. M., Jakobs, C., & DeGrauw, T. J. (2001) · Annals of Neurology · doi:10.1002/ana.79 · Cited by 181
Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiology
Stockler, S., Schutz, P. W., & Salomons, G. S. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_8 · Cited by 180
Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency
Skelton, M. R., Schaefer, T. L., Graham, D. L., deGrauw, T. J., Clark, J. F., Williams, M. T., & Vorhees, C. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016187 · Cited by 124
Brun, É., Carrière, M., & Mabondzo, A. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.025 · Cited by 124
Self-citationCyclocreatine treatment improves cognition in mice with creatine transporter deficiency
Kurosawa, Y., DeGrauw, T. J., Lindquist, D. M., Blanco, V. M., Pyne-Geithman, G. J., Daikoku, T., Chambers, J. B., Benoit, S. C., & Clark, J. F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59373 · Cited by 98
Research works printed but not linked: 1
- Ohtsuki S., 2002, J. Cereb. Blood Flow. Metab., 22, 1327, 10.1097/01.WCB.0000033966.83623.7D · doi:10.1097/01.wcb.0000033966.83623.7d · Paper page
Cited by
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Creatine biosynthesis and transport in health and disease
Joncquel-Chevalier Curt, M., Voicu, P.-M., Fontaine, M., Dessein, A.-F., Porchet, N., Mention-Mulliez, K., Dobbelaere, D., Soto-Ares, G., Cheillan, D., & Vamecq, J. (2015) · Biochimie · doi:10.1016/j.biochi.2015.10.022 · Cited by 238
Račkayová, V., Cudalbu, C., Pouwels, P. J. W., & Braissant, O. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.11.007 · Cited by 144
X‐linked creatine transporter deficiency: clinical aspects and pathophysiology
van de Kamp, J. M., Mancini, G. M., & Salomons, G. S. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9713-8 · Cited by 118
“Unfortunately, the creatine esters are subject to rapid degradation to creatinine (Lunardi et al 2006; Adriano et al 2011; Trotier-Faurion et al 2013) and no effect of treatment with creatine-ethyl-ester was found in CRTR-D patients (Fons et al 2010).”
Current and potential new treatment strategies for creatine deficiency syndromes
Fernandes-Pires, G., & Braissant, O. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.12.005 · Cited by 72
Hanna-El-Daher, L., & Braissant, O. (2016) · Amino Acids · doi:10.1007/s00726-016-2189-0 · Cited by 65
“…or transported by lipid nanocapsules) which would allow the crossing of plasma membrane independently of SLC6A8 while achieving Cr roles within CNS. (Perasso et al. 2008, 2009; Adriano et al. 2011; Burov et al. 2011; Vlasov et al. 2011; Kurosawa et al. 2012; Trotier-Faurion et al. 2013, 2015).”
Creatine Supplementation in Children and Adolescents
Jagim, A. R., & Kerksick, C. M. (2021) · Nutrients · doi:10.3390/nu13020664 · Cited by 61
“F r example, r cent work ha demo strated early promise with the use of creatine fatty esters and lipid nanocapsules as a nutrition-based therapeutic treatment for creatine transporter deficiency [55,56].”
BackgroundThe Creatine Transporter Unfolded: A Knotty Premise in the Cerebral Creatine Deficiency Syndrome
Farr, C. V., El‐Kasaby, A., Freissmuth, M., & Sučić, S. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.588954 · Cited by 58
Sharer, J. D., Bodamer, O. A., Longo, N., Tortorelli, S., Wamelink, M. M. C., & Young, S. P. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.203 · Cited by 44
Udobi, K. C., Kokenge, A. N., Hautman, E. R., Ullio, G., Coëne, J., Williams, M. T., Vorhees, C. V., Mabondzo, A. M., & Skelton, M. R. (2018) · Genes Brain & Behavior · doi:10.1111/gbb.12461 · Cited by 53
“Cr and GAA content were assayed in brain, heart, and kidney using a UPLC-MS/MS method(Trotier-Faurion et al., 2013).”
Self-citationUllio-Gamboa, G., Udobi, K. C., Dézard, S., Perna, M. K., Miles, K. N., Costa, N., Taran, F., Pruvost, A., Benoît, J., Skelton, M. R., et al. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0059 · Cited by 41
Self-citationXie, F., Yan, F., Chen, M., & Zhang, M. (2014) · RSC Advances · doi:10.1039/c4ra04618h · Cited by 33
Trotier-Faurion, A., Passirani, C., Béjaud, J., Dézard, S., Valayannopoulos, V., Taran, F., de Lonlay, P., Benoit, J.-P., & Mabondzo, A. (2015) · Nanomedicine · doi:10.2217/nnm.13.205 · Cited by 31
Self-citationProdrugs and their activation mechanisms for brain drug delivery
Lillethorup, I. A., Hemmingsen, A., & Qvortrup, K. M. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00788c · Cited by 28
Udobi, K. C., Delcimmuto, N., Kokenge, A. N., Abdulla, Z. I., Perna, M. K., & Skelton, M. R. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12137 · Cited by 25
Ghirardini, E., Calugi, F., Sagona, G., Vetta, F. D., Palma, M., Battini, R., Cioni, G., Pizzorusso, T., & Baroncelli, L. (2021) · Genes · doi:10.3390/genes12081123 · Cited by 38
Nota, B., Ndika, J., van de Kamp, J. M., Kanhai, W. A., van Dooren, S. J. M., van de Wiel, M. A., Pals, G., & Salomons, G. S. (2014) · Human Mutation · doi:10.1002/humu.22609 · Cited by 14
Mabondzo, A. M., Harati, R., Broca-Brisson, L., Guyot, A.-C., Costa, N., Cacciante, F., Putignano, E., Baroncelli, L., Skelton, M. R., Saab, C., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1118707 · Cited by 14
“DCE was prepared as previously described (Trotier-Faurion et al., 2013).”
Self-citationThink Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases
Faouzi, A., & Roullin, G. (2021) · Pharmaceuticals · doi:10.3390/ph14020109 · Cited by 14
Adriano, E., Salis, A., Damonte, G., Millo, E., & Balestrino, M. (2022) · Brain Sciences · doi:10.3390/brainsci12010085 · Cited by 10
“However, we hypothesized that if we modified the guanidinoacetic acid molecule and rendered it lipophilic it might cross the blood–brain barrier and cell plasma membranes independently of the transporter, in a fashion similar to creatine-derived, lipophilic molecules [17,18].”
BackgroundDisdier, C., Lhotellier, C., Guyot, A.-C., Costa, N., Théodoro, F., Pruvost, A., Skelton, M. R., Joudinaud, T., Mabondzo, A. M., & Bénech, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117195 · Cited by 8
Self-citationBroca-Brisson, L., Harati, R., Disdier, C., Mózner, O., Gaston-Breton, R., Maïza, A., Costa, N., Guyot, A.-C., Sarkadi, B., Apáti, Á., et al. (2023) · eLife · doi:10.7554/elife.88459 · Cited by 7
Self-citationBroca-Brisson, L., Disdier, C., Harati, R., Hamoudi, R., & Mabondzo, A. M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1362497 · Cited by 6
Self-citationDisdier, C., Soyer, A., Broca-Brisson, L., Goutal, S., Guyot, A.-C., Ziani, N., Breuil, L., Winkeler, A., Hugon, G., Joudinaud, T., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106720 · Cited by 5
Self-citationDisdier, C., Lhotellier, C., Wagner, S., Andriambeloson, E., Théodoro, F., Pruvost, A., Joudinaud, T., Bénech, H., & Mabondzo, A. M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1597263 · Cited by 4
Self-citationBénech, H., Flament, V., Lhotellier, C., Roucairol, C., & Joudinaud, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010080 · Cited by 3
Lai, M., Su, F., Hu, J., Wang, M., Zhao, M., & Zhang, G. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2021.822625 · Cited by 3
Broca-Brisson, L., Harati, R., Disdier, C., Mózner, O., Gaston-Breton, R., Maïza, A., Costa, N., Guyot, A.-C., Sarkadi, B., Apáti, Á., et al. (2023) · eLife · doi:10.7554/elife.88459.1 · Cited by 3
Self-citationDodecyl creatine ester therapy: from promise to reality
Mabondzo, A. M., van de Kamp, J. M., & Mercimek‐Andrews, S. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05218-y · Cited by 2
“Dodecyl creatine ester (DCE) is a prodrug of creatine selected from a library of creatine prodrugs that link the hydroxyl group of creatine with a dodecyl alcohol, making the lipophilic ester [15].”
BackgroundSelf-citationBlood–Brain Barrier Transporters and Central Nervous System Drug Response and Toxicity
Miller, D. W., Line, S., Safa, N. A., & Zhang, Y. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch12 · Cited by 1
Creatine Deficiency Syndromes: A Clinical, Molecular and Functional Approach
Ndika, J. (2014) · Pure Amsterdam UMC
Trotier-Faurion, A. (2013) · theses.fr (ABES) · doi:10.70675/88744a8azcb26z49dbz977az6bf9162d955c
Self-citationBénech, H., Krebs-Drouot, L., Viardot, G., Bertaina‐Anglade, V., Lhotellier, C., Flament, V., Roucairol, C., Mabondzo, A., Pinquier, J., & Joudinaud, T. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1940627
“CBT101 consists of the dodecyl creatine ester hydrochloride (14) formulated as a particulate oil-in-water emulsion (15).”
Self-citation
Metadata
- Authors
- Trotier-Faurion, A., Dézard, S., Taran, F., Valayannopoulos, V., de Lonlay, P., & Mabondzo, A.
- Affiliations
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Hôpital Necker-Enfants Malades (FR)
- Centre de Référence des Maladies Héréditaires du Métabolisme de l′Enfant et de l′Adulte, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France
- Corresponding author
- Mabondzo, Aloïse
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-06-07
- Volume
- 56
- Issue
- 12
- Pages
- 5173-5181
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1998558126
- Cited by
- 36
- References
- 25
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 5
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- creatine transporter deficiency, SLC6A8, prodrugs, blood-brain barrier permeability, neurons, astrocytes, structure-activity relationship, creatine deficiency, drug candidates, organic synthesis
- MeSH terms
- Animals, Blood-Brain Barrier, Cell Survival, Creatine, Creatinine, Drug Stability, Esters, Female, Humans, Pregnancy, Membrane Transport Proteins, Rats, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.